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Abstract. The aim of this study was to compare the 
intensity of typical late complications in diabetic 
patients (/? = 65, 28 type I, 37 type II) who were not 
on glycoside drugs with low vs. high serum levels of 
digoxin-like immunoreactive factor (DLIF : group I, 
n = 42, D L I F ^ the detection limit of 0*2 ng m l 1 ; and 
group II, // = 23, m e a n i S E M : H 7 ± 0 - 3 1 [0-25-4-96] 
ng ml" 1 ) . For detection of nephropathy, urinary 
albumin excretion (24 h) and creatinine clearance 
tests were used. For coronary heart disease a ques-
tionnaire and standard E C G ; for peripheral occlusive 
vascular disease a questionnaire; for eye disease a 
fundoscopy; for neuropathy a neurological score 
system; and for autonomic neuropathy a standardized 
test battery was employed. Patients with high D L I F 
levels showed better test results in vibratory perception 
(95-7±l-5 vs. 82-8±3-8%, normal finding = 100%, 
2p = 0016), had better percentile localizations concern-
ing maximal pupillary area in darkness (28-4±6-6 vs. 
8-1 ±1-8%, 2p = 0-0004), contraction velocity at 1 s 
(21-5±5-8 vs. 8-0±2-2%, 2p = 0-012), and dilation 
velocity at 6 s (23-0±6-8 vs. 10-5±2-5%, 2p = 0-041), 
had less retinopathy (with retinopathy: 26-1% vs. 
64-3%, 2p = 0-0028), and better percentile localiza-
tions in the respiratory sinus arrhythmia test 
(68-4±7*3 vs. 44-1 ± 4 9 % , 2p = 0-0064). There was no 
difference concerning nephropathy, blood pressure, 
coronary heart disease and peripheral vascular dis-
ease. Separate analysis according to the type of dia-
betes confirmed the results in each group. This would 
indicate that D L I F is a possible protective endogenous 
substance for eye disease, and peripheral (large sensory 
fibres) and autonomic neuropathy in diabetic subjects 
independent of the type of diabetes. 
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Introduction 
The sodium-potassium pump is responsible for the 
gradient of monovalent ions between intracellular and 
extracellular fluids. Three sodium ions are translo-
cated outwards against two potassium ions inwards 
per one A T P molecule hydrolysed [1]. This ubiquitous 
transport system plays a major role in regulating body 
water content and several cell functions including 
control of cell volume, excitability and nutrition. 
Dysfunctions of the pump stem either from intrinsic 
membrane alterations, action of humoral factors, or 
both dysfunctions. Endogenous pump inhibitors, the 
so-called digoxin-like immunoreactive factors 
(DLIF) , have been described in several tissues, such 
as brain [2-4], kidney [5], adrenal gland [6], and in 
biological fluids [7-9]. Furthermore, D L I F was found 
in several physiological and pathophysiological con-
ditions including newborn infants [10], pregnant 
women [11], hypertensive pregnant women [12], 
renal failure [13,14], liver disease [15-17], essential 
hypertension [18-23], diabetes [24-26], obstructive 
sleep apnoea [27], acromegaly [28] and aneurysmal 
subarachnoid haemorrhage [29]. 
With the exception of a recently found endogenous 
ouabain-like compound [30], the chemical nature of 
digoxin-like immunoreactive factors is not yet known. 
Therefore, it is not possible to perform specific R I A 
assays for D L I F by use of antisera against D L I F , with 
D L I F as standard. However, it was found that there 
exists a good correlation between endogenous 
digoxin-like immunoreactivity measured by digoxin 
R I A and 3 H-ouabain displacement on erythrocyte 
membranes in humans [31]. In accordance with Cler-
ico et al. [32], it is thought that digoxin R I A methods 
can be useful for D L I F determination because they 
are generally more sensitive, precise and simple than 
other techniques used to detect endogenous digitalis-
like factors. However, immunological methods should 
be used only as preliminary tests to detect the possible 
presence of D L I F in human biological fluids. 
In this respect it was the aim of the study to 
compare the intensity of typical late complications 
in diabetic patients, with and without measurable 
serum digoxin, using a standard immunological 
method. Known interference from drugs or severe 
disease states have been widely ruled out. 
Patients and methods 
Patients 
Sixty-five diabetic outpatients (28 type I, 37 type II) 
with a mean age of 47 1 ±2-2 years (14-76 y) were 
studied after they had given informed consent. The 
clinical parameters of patients under study are shown 
in Table 1. None of these 65 patients received cardiac 
glycosides, spironolactone, prednisone or cortisone 
which is known to interfere with detection of digoxin 
immunoreactivity. Because of possible false positive 
measurements, all the patients were ensured to have 
near normal levels of serum triglycerides, serum 
cholesterol, haemoglobin A l e , serum sodium, serum 
potassium, serum bilirubin, serum protein, serum 
albumin, haemoglobin, leucocytes, platelets and hae-
matocrit. The groups did not differ statistically sig-
nificantly in the above-mentioned laboratory 
parameters. High sodium intake is known to increase 
the plasma concentration of Na/K-ATPase inhibitor 
[21]. Therefore, sodium diet might influence the 
results. Hence, 24 h urinary sodium and potassium 
excretion have to be similiar in the two study groups 
(Na: group I vs. group II: 137-4±ll-8 vs. 140-7±14-0 
m m o l d - 1 ; K : 53-7±5-9 vs. 61-9±5-4 m m o l d 1 ) - None 
of the patients had severe pre-terminal renal failure 
(exclusion of patients with serum creatinine greater 
than 3-Omgdl - 1 , serum urea greater than l O O m g d H 
and/or nephrotic proteinuria) or hepatic disease or 
pregnancy, and all had normal serum electrolyte 
levels. Furthermore, the presence of ventricular dys-
function was widely ruled out and from clinical 
aspects the patients had mild to moderate congestive 
heart failure distributed equally in both groups 
(exclusion of patients with heart failure of more 
than N Y H A functional class II). The patients were 
then divided into two groups according to their level 
of digoxin immunoreactivity. The first group con-
sisted of patients with a D L I F levels the detection 
limit of 0-2 ng m l " 1 (n — 42) and the second group of 
patients with D L I F above 0-2 ng ml J (n = 23). They 
were not different in clinical parameters (Table 1). 
Patients' specimens 
On the day the patients returned their 24 h urine 
collection (08 00 hours), which they undertook a day 
before, a urine specimen was taken for the determina-
tion of urine creatinine, urine albumin, urine sodium 
and urine potassium. Furthermore, blood was drawn 
at the same time for the determination of serum 
cholesterol, serum triglycerides, haemoglobin A l e , 
serum creatinine for endogenous creatinine clear-
ance, serum sodium, serum potassium, serum biliru-
bin, total serum protein, serum albumin, 
haemoglobin, leucocytes, platelets and haematocrit 
using standard techniques. 
Measurement of digoxin-like immunoreactive factor 
Several studies showed that the T D X system (Abbott 
G m b H Diagnostika, Wiesbaden, Germany) can mea-
sure D L I F , but compared to other immunological 
techniques the interference was generally less than 
that seen in commonly used RIAs for digoxin [33, 
34]. This may be due to the recommended removal of 
serum proteins for the use of this technique [35]. The 
cross-reactivity of the T D X system for cholesterol, 
Cortisol, dehydroepiandrosterone sulfate, estriol, 
prednisolone, progesterone, 11 -o>hydroxyprogester-
one, 17-r*-hydroxyprogesterone and testosterone was 
below 1 %. The coefficient of variation for this kit was 
clearly below 8% and the average analytical recovery 
of digoxin was about 100%. Hence, in order to 
minimize interferences the T D X system was used in 
this study. 
Before digoxin immunoreactivity measurement by 
Table 1. Clinical parameters ( m e a n ± S E M ) of patients under study. Percentages are given in 
parentheses and ranges in brackets. D L I F , digoxin-like immunoreactive factor 
D L I F ^ the detection D L I F above detection 
limit of 0-20ngml- ] limit of 0-20ngml- ] 
D L I F [ n g m l '] ^ 0 - 2 0 n g m H 1-17 ±0 -31 [0-25-4-9] 
n 42 (64-6%) 23 (35-4%) 
Age[y] 48-8 ± 2 - 6 43-9 ± 41 
Female 30(71-4%) 14(60-9%) 
Male 12 (28-6%) 9(39-1%) 
Body mass index [kgrn" 2 ] 25-6 ± 0 - 8 24-4 ± 11 
Duration [y] 14-4 ± 1 - 5 15-8 ± 2 - 6 
Type [1/II] 18/24 (42-9% 571 %) 10/13 (43-5%/56-5%) 
Smoker 9(21-4%) 7(30-4%) 
Daily insulin need [IU] (all types of diabetes) 28-7 ± 3-6 25-5 ± 3-9 
Patients under sulphonylureas 11 (26-2%) 6 (261%) 
Patients under metformin 2 (4-8%) 1 (4-3%) 
fluorescence polarization immunoassay (FPIA), 
serum protein was precipitated using 5-sulfosalicylic 
acid in equivolume methanol/water in accordance 
with the manufacturer's recommendations. This mix-
ture was centrifugated at 9500 at 20°C and digoxin 
was measured in the resulting supernate. A l l the 
digoxin determinations were carried out with the 
Abbott T D X analyser with original Abbott F P I A 
reagents. F P I A digoxin immunoreactivity in 
patients' samples was extrapolated from fluorescence 
polarization data stored in the T D X , consisting of 
analytical standards from Abbott: 00 , 05 , 10, 2*0, 
3*0 and 5*0 ng m l 1 . Standard T D X software com-
pensated for twofold dilution of the sample with 5-
sulfosalicylic acid in reporting digoxin results. The 
detection limit for digoxin recommended by the 
manufacturer for 5-sulfosalicylic acid precipitation 
and F P I A method was 0*2 ng m l 1 . This detection 
limit is confirmed by others [36]. 
Evaluation of diabetic late complications 
For the detection of nephropathy, 24 h urinary 
albumin excretion and endogenous creatinine clear-
ance are used; for coronary heart disease a question-
naire and standard 12-lead electrocardiograms at rest; 
for peripheral occlusive vascular disease a question-
naire; and for eye disease the evaluation of the fundus 
by an ophthalmologist were used. Autonomic neuro-
pathy was assessed by a battery of tests including 
standardized cardiovascular (variation coefficient of 
R - R intervals, respiratory sinus arrhythmia 
test = R S A , Valsalva test lying-to-standing test; [37]) 
and pupillometric investigations (latency time of 
pupillary light reflex, maximal pupillary area in dark-
ness, contraction velocity at 1 s, dilation velocity at 6 s 
[38]). Peripheral neuropathy was assessed by measur-
ing test groups as vibratory perception with a tuning 
fork (left and right: great toe, medial malleolus, 
medial epicondyle of the femur), temperature percep-
tion by means of a cold (22°C) and warm (30CC) metal 
disc (left and right: back of the foot, tibia, back of the 
hand, fingers) and reflexes (biceps brachii, triceps 
brachii, quadriceps femoris, triceps surae). On each 
of the mentioned three test groups a patient can 
obtain 100 points which indicates a completely 
normal function (=100% function). According to 
an international consensus conference, patients with 
24 h urinary albumin excretion of more than 30 mg 
d~- were said to have albuminuria [39]. 
Statistical analysis 
Multiple group means were compared by ANOVA 
(SPSS/PC + Advanced Statistics V4-0, SPSS Inc., 
Chicago, I N , U S A ) . For autonomic function tests, 
the exact percentile localization derived from data of 
earlier studies were used [37,38]. Values are expressed 
as m e a n ± S E M unless otherwise stated and 2p = 005 
is the significant level 
Results 
Frequency and level of measurable DLIF 
From a total of 28 type I diabetic patients 10 (35*7%) 
and from 37 type II diabetic patients 13 (351%) had a 
measurable D L I F level (all patients together: 35-4%). 
The average level in the 10 type I diabetic patients was 
l l ± 0 - 4 ng m l 1 (0-25-4-6) and l-2±0-4 ng m l 1 
(0-25-4-96) in the 13 type II diabetic patients, respec-
tively. The average level in all patients with a measur-
able D L I F was L2±0-3 ng m l 1 . 
Diabetic late complications 
Table 2 summarizes the data of patients with an 
undetectable D L I F level and those with a measurable 
D L I F level. There was no difference in endogenous 
creatinine clearance, 24 h urinary albumin excretion, 
frequency of peripheral occlusive vascular disease 
(pOVD) and coronary heart disease ( C H D ) between 
the two groups. Furthermore, the two groups were 
not different in systolic and diastolic blood pressure 
but a trend towards higher values in the group with 
low D L I F level seemed to exist. Retinopathy was 
clearly more frequent in patients with a low D L I F 
level (2p = 0*003). Beyond that, pupillometric para-
meters as maximal pupillary area (2p = 00004), con-
traction velocity at 1 s (2p = 0012), dilation velocity at 
6 s (2p = 0-041) and the result of the cardiorespiratory 
R S A test (2p = 0*006) were much better in patients 
with a measurable D L I F than in those with an 
undetectable level. The clinical neurological tests 
revealed a better test result in sensory large fibre 
function (vibration perception) in patients with high 
D L I F levels (2p = 0*016). In all the neurological tests 
(autonomic and peripheral) where no significant 
difference could be found, a trend towards better 
test results in diabetic patients with a high D L I F 
level seemed to exist. This is also true for the 24 h 
urinary albumin excretion, which differed nearly 
statistically significantly in type II diabetic patients 
(patients with a 24 h urinary albumin excretion of 
more than 30 mg d 1 : group I vs. II: 73*9% vs. 41*7%, 
2p = 0-067). 
Figure 1 shows the results of fundoscopy and 
vibration perception testing of type I and type II 
diabetic patients with a high and low D L I F level. 
Type I diabetic patients with high D L I F levels had 
significantly less retinopathy than patients with low 
D L I F levels (300% vs. 70-6%, 2p = 0*042). This could 
also be confirmed in type II diabetic patients (231% 
vs. 62-5%, 2p= 0022). Considering vibratory percep-
tion, type II diabetic patients with high D L I F level 
had better sensory large fibre function than patients 
with low D L I F (94*5 vs. 78-6%, 2p - 0036). This was 
not statistically significant in the smaller group of type 
I diabetic patients but there was a similar trend. 
With regard to autonomic neuropathy, the max-
imal pupillary area was higher in type I and type II 
Table 2. Parameters ( m e a n i S E M ) of diabetic late complications of patients under study. Percentages are shown in parentheses. D L I F , digoxin-
Hke immunoreactive factor; p O V D , peripheral occlusive vascular disease; C H D , coronary heart disease; R S A , respiratory sinus arrythmia; Pe, 
percentile localization in [%] 
D L I F 5 $ the detection D L I F above detection 
limit of 0 - 2 0 n g m H limit of 0 - 2 0 n g m H 2P 
Kidney disease 
Patients with a creatinine clearance of less than 7 0 m l m i n _ 1 
Patients with a 24 h urinary albumin excretion of more than 30mgd 
Cardiovascular disease 
Systolic blood pressure [mmHg] 
Diastolic blood pressure [mmHg] 
Patients with a systolic blood pressure of more than 140 mmHg 
Patients with a diastolic blood pressure of more than 90 mmHg 
With p O V D 
With C H D 
Eye disease 
With retinopathy (all stages) 
Autonomic neuropathy 
Pupillary 
Pe. in latency time 
Pe. in maximal pupillary area 
Pe. in contraction velocity at 1 s 
Pe. in dilation velocity at 6 s 
Cardiorespiratory 
Pe. in R S A test 
Pe. in var. coefT. of R - R intervals 
Pe. in Valsalva test 
Pe. in Ewing test 
Neuropathy 
Vibratory perception [%] 
Reflex status [%] 
Temperature perception [%] 
21-9% 130% 0-389 
65-0% 45-5% 0-140 
138 0 ± 3 - 5 132-6 ± 4 - 0 0-341 
80-3 ± 1-9 77-2 ± 2 - 3 0-316 
38-1% 30-4% 0-554 
11-9% 4-4% 0-322 
7 (16 7%) 5 (21-7%) 0-621 
10(23-8%) 6 (261%) 0-842 
27 (64-3%) 6(26-1%) 0-003 
24-0 ± 4 - 3 21-1 ± 4 - 3 0-665 
8-1 ± 1-8 28-4 ± 6 - 6 0-0004 
8 0 ± 2 - 2 21-5 d= 5-8 0-012 
10-5 ± 2-5 23-0 ± 6 - 8 0-041 
44-1 ± 4 - 9 68-4 ± 7-3 0006 
3 3 - 8 ± 5 1 4 4 - 8 ± 6 - 5 0-196 
27-6 ± 4 - 1 30-5 ± 5-9 0-676 
20-9 ± 4 - 4 28-4 ± 6 - 2 0-324 
82- 8 ± 3-8 95-7 ± 1-5 0-016 
78-3 ± 3-2 80-4 ± 5 - 1 0-713 
83- 8 ± 2 - 7 89-4 ± 4 - 1 0-240 
diabetic patients with high compared to low D L I F 
levels (type I: 30-1 vs. 7-8% percentile, 2p = 0-031 and 
type II: 27-0 vs. 8-5% percentile, 2p= 0007, Fig. 2). 
This could be confirmed in type II diabetic patients 
considering the test results in R S A test (high D L I F : 
681 vs. low D L I F : 35-7% percentile, 2p= 0007). 
Discussion 
65 type I and type II diabetic patients were screened 
for digoxin-like immunoreactive factor. About 35% 
of all patients showed a measurable D L I F level with 
an average of 1-2 ng m l 1 . It was shown that patients 
with high D L I F levels in serum had less severe late 
complications compared to those with a low D L I F 
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Figure 1. Results in patients with high and low levels of digoxin-like 
immunoreactive factor ( D L I F ) in type I and type II diabetic 
patients. (Left) Percentage of type I and type II diabetic patients 
with retinopathy. (Right) Result in the vibratory perception test in 
type I and type II diabetic patients. According to the definition, a 
finding of 100% is normal and a finding below 80% is neuropathic. 
low DLIF 
high DLIF 
low DLIF 
high DLIF 
Figure 2. Results in patients with high and low levels of digoxin-like 
immunoreactive factor ( D L I F ) in type I and type II diabetic 
patients. (Left) Average percentile localization of maximal pupil-
lary area in darkness. (Right) Average percentile localization in the 
autonomic function test of respiratory sinus arrhythmia. 
serum level, especially regarding retinopathy and 
autonomic and peripheral neuropathy. This could 
also be confirmed when dividing the total group in 
type I and type II diabetic subgroups. Retinopathy, 
peripheral and autonomic neuropathy seem to be the 
only complications linked with the D L I F levels. 
However, the correlation between nephropathy and 
D L I F seems to exist at least in form of a trend. 
Moreover, if coronary heart disease and peripheral 
occlusive vascular disease were assessed with the same 
accurate techniques, which were not available, com-
pared to the assessment of neuropathy, retinopathy 
and nephropathy a difference between the two groups 
might be demonstrable concerning the two late com-
plications. To our knowledge, this is the first study 
that compares late complication in diabetic patients 
with respect to different D L I F serum levels. There 
have been several reports showing that D L I F was 
high in patients with essential hypertension [18-23] 
and one group had shown that type II diabetic 
patients with a family history of hypertension had 
higher D L I F levels [25]. It has been shown that 
patients with acromegaly and chronic volume expan-
sion have decreased levels of D L I F and plasma 
volume after pituitary adenomectomy [28]. Further-
more, pregnant women and their newborn infants 
have high D L I F levels which decrease rapidly after 
birth [10,11]. This may be also due to volume expan-
sion in the perinatal period. From animal experiments 
it is known that volume expansion and salt-loading 
increases D L I F levels [4,7,8]. This could also be 
confirmed in humans [40]. From this point of view, 
D L I F levels seem to be increased secondarily in salt-
loaded and volume-expanded subjects and probably 
not vice versa. Nevertheless, it should be mentioned 
that there are some studies which argue against the 
volume expansion hypothesis. It is said that D L I F 
lead to exaggerated vascular smooth muscle contrac-
tion and to an elevation of peripheral vascular resis-
tance due to an increase in cytosolic free calcium 
concentration [41]. Furthermore, reducing the 
sodium pump activity may exaggerate neural stimula-
tion and norepinephrine overflow [42] which, together 
with increased vascular resistance, might explain, at 
least in part, hypertension. But it is still a matter of 
debate whether D L I F is primarily high in some 
subjects then perhaps leading to hypertension, or 
secondarily as a consequence of volume expansion 
to counteract hypertension. 
In diabetes mellitus there are some important 
factors for volume expansion which are increased 
insulin level, increased growth hormone level, 
increased sympathetic activity and high water intake 
because of high blood glucose levels [2,8,20,30,43-52]. 
Moreover, it is possible that inadequately high Corti-
sol production rates as found in obese subjects [53] 
may contribute to volume expansion in type II 
diabetic patients, too. In later disease states, severe 
diabetic nephropathy also leads to volume expansion, 
but this appeared to be of no importance in this study. 
These mechanisms have to be counteracted by a 
feedback control system that protects the subject 
from hypertension. The antagonistic factors leading 
to volume contraction are inhibition of the secretion 
of vasopressin, renin and aldosterone, stimulation of 
the secretion of atrial natriuretic peptide and digoxin-
like immunoreactive factor(s), and local renal prosta-
glandin ( E l , E2, 12) mechanisms [2,20,30,44,52]. 
In conclusion, and under consideration of the recent 
report showing that D L I F may be in part endogenous 
ouabain [30], lack of D L I F secretion in diabetic 
patients may be a factor leading to alterations in 
regulation of body water content and several cell 
functions including control of cell volume, excitability 
and nutrition due to intracellular and extracellular 
volume expansion. This in fact may lead to a diffusion 
barrier for vital nutrients in susceptible bradytrophic 
tissues such as retina and nerve. Hence, diabetic 
patients with low D L I F of unknown origin may be 
more susceptible for late complications due to volume 
expansion and lowered tissue perfusion. The somewhat 
speculative question arises as to whether administration 
of low doses of digoxin or ouabain may be protective in 
diabetic patients. Before administration of such drugs 
in a controlled prospective study, a larger cross-sec-
tional survey would have to confirm our findings. 
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